X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ADIL

Closed

Adial Pharmaceuticals Inc

0.3163
+0.0141 (+4.67%)
Last Update: 01 Jul 2025 23:21:00
Yesterday: 0.3022
Day's Range: 0.2715 - 0.3997
Send
When Written:
 
0.3579
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of treatments for addiction and related disorders. The company's lead product candidate is AD04, a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is designed to block the effects of alcohol on specific receptors in the brain, which may reduce the desire to drink and help people with AUD abstain from alcohol.

Adial Pharmaceuticals was founded in 2010 and is headquartered in Charlottesville, Virginia. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol ADIL. In addition to AD04, Adial Pharmaceuticals is also developing other drug candidates for the treatment of addiction and related disorders, including opioid use disorder and cocaine use disorder.

The company has partnerships with academic institutions and research organizations to advance its drug development programs, and has received funding from the National Institutes of Health (NIH) and other government agencies. Adial Pharmaceuticals is led by a team of experienced pharmaceutical executives and scientists, including CEO William Stilley and Chief Medical Officer Bankole Johnson.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X